Home / Conditions / Prostate Problem
Prostate Problem: when insurers say no, reviewers often say yes
In 33 published external-review decisions involving prostate problem, independent physician reviewers overturned the insurer’s denial 45.5% of the time.
Published decisions
33
2001–2026
Overturned
45.5%
15 denials reversed
Most-fought treatments for prostate problem
What insurers denied — and how those fights ended.
| Category | Decisions | Overturned |
|---|---|---|
| Erectile Dysfunct Rx | 5 | 60% |
| Genetic Genomic Test | 4 | 0% |
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 18 | 50% |
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 14 | 42.9% |
Typical time to a decision
21 days
Most land between 15 and 22 days
Handled as urgent
12.1%
Expedited when a delay would cause harm
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
The patient is a 63-year-old male who has been diagnosed with prostatic enlargement, gross hematuria, and bladder outlet obstruction. On 5/23/19, the patient underwent cystoscopy and transurethral resection of the prostate (TURP). The patient required continuous bladder irrigation on postoperative day one. He was given a void trial on 5/25/19 and discharged home. The patient has requested reimbursement for an inpatient hospital stay from 5/24/19 through 5/25/19. The Health Plan denied this request and reported that the services at issue were not medically necessary for the treatment of this patient. At issue in this case is whether an inpatient hospital stay from 5/24/19 through 5/25/19 was medically necessary for the treatment of the patient’s medical condition. Hematuria is the most common complication of TURP procedures in the immediate postoperative period.
Nature of Statutory Criteria/ Case Summary: The enrollee requests authorization and coverage for the UroLift procedure. According to the enrollee’s medical record, the enrollee is diagnosed with benign prostatic hyperplasia (BPH) with severe obstructive symptoms. He was told 20 years ago that he has a congenital deformity of the median lobe. He has urinary frequency, nocturia, and incontinence. He received treatment from multiple urologists and tried four medications (Proscar, Avodart, Flomax, and Cardura). He had not pursued surgery before because he was concerned for retrograde ejaculation; however, his symptoms have worsened. The enrollee states that because of his age and history of sleep apnea, he cannot tolerate the general anesthesia required for a transurethral resection of the prostate (TURP) procedure.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/ Case Summary: The enrollee is requesting reimbursement and authorization and coverage for the daily use of Cialis (Tadalafil). The enrollee has prostate pain, initially seen with complaints of bladder pressure, constipation, fatigue, nocturia, sexual dysfunction, urinary frequency and urinary urgency. Cialis was prescribed. A follow up visit indicated symptoms had improved with Kegel exercises. The enrollee did not want to take Finasteride or similar medications due to risk of impotence on the side effects list. He was experiencing sexual dysfunction, urinary dribbling and urinary frequency. Review of the enrollee’s active medications in the record shows the provider prescribed Finasteride tablet. The provider’s assessment/plan on a follow up visit indicates the enrollee requested Cialis.
Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for Genetic testing (Oncology (prostate) gene expression profile by real-time polymerase chain reaction (RT-PCR) of three genes (ERG, PCA3, and SPDEF), urine, algorithm reported as risk score). This patient presents with elevated prostate specific antigen (PSA) and benign prostatic hyperplasia (BPH). The patient underwent ExoDx testing, which revealed a 91% chance of no high grade prostate cancer. As noted in the peer-reviewed medical literature, the use of ExoDx testing to forego biopsy in patients with increasing PSA and negative magnetic resonance imaging (MRI) has not been demonstrated to improve clinical patient health outcomes.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
How to use this in your appeal
These outcomes come from California’s external review program — an independent physician panel whose decision binds the insurer. Every state has an equivalent, and internal appeals succeed even more often. If your care for prostate problem was denied, the published record says the denial is worth fighting.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.